Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Purchases 9,000 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour bought 9,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average price of $5.54 per share, with a total value of $49,860.00. Following the purchase, the chief executive officer owned 3,096,000 shares of the company’s stock, valued at approximately $17,151,840. This represents a 0.29% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Neonc Technologies Stock Performance

Neonc Technologies stock opened at $5.53 on Wednesday. The stock’s fifty day moving average is $4.14 and its two-hundred day moving average is $6.02. Neonc Technologies Holdings, Inc. has a 1-year low of $3.01 and a 1-year high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Hedge Funds Weigh In On Neonc Technologies

A number of large investors have recently bought and sold shares of NTHI. Bank of America Corp DE boosted its holdings in Neonc Technologies by 1.0% in the 3rd quarter. Bank of America Corp DE now owns 226,486 shares of the company’s stock valued at $2,056,000 after purchasing an additional 2,207 shares in the last quarter. State Street Corp raised its stake in shares of Neonc Technologies by 9.9% during the 4th quarter. State Street Corp now owns 43,170 shares of the company’s stock worth $357,000 after buying an additional 3,900 shares in the last quarter. Barclays PLC lifted its holdings in shares of Neonc Technologies by 5,314.8% in the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock valued at $76,000 after buying an additional 8,982 shares during the period. Goldman Sachs Group Inc. acquired a new position in Neonc Technologies during the fourth quarter worth $124,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Neonc Technologies during the fourth quarter worth $126,000.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NTHI. BTIG Research reissued a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, May 26th. Weiss Ratings downgraded Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 24th. Wall Street Zen cut Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Alliance Global Partners began coverage on shares of Neonc Technologies in a report on Tuesday, May 19th. They issued a “buy” rating and a $13.00 target price on the stock. Finally, Maxim Group assumed coverage on shares of Neonc Technologies in a research report on Monday, May 18th. They issued a “buy” rating and a $20.00 price target for the company. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Neonc Technologies currently has a consensus rating of “Hold” and an average target price of $16.00.

Neonc Technologies News Roundup

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: NEO100 reached a Phase 2a endpoint: The company reported that NEO100 produced positive Phase 2a results in recurrent IDH1-mutant high-grade glioma, including extended survival. The update strengthens the investment case for NeOnc’s central-nervous-system drug platform and could support further development or partnership interest. Neonc NEO100 Hits Phase II Endpoint, Extends Survival in Recurrent Glioma
• Positive Sentiment: Repeated CEO insider buying is supporting sentiment: Heshmatpour purchased 12,000 shares on August 14 for approximately $45,480, 3,000 shares on August 17 for $13,110, and another 9,000 shares on August 18 for $49,860. The purchases increased his already substantial ownership and signal management confidence, although insider buying does not guarantee clinical or financial success. SEC Form 4 Filing
• Neutral Sentiment: Analyst views remain mixed: Several firms maintain Buy ratings and price targets ranging from $13 to $20, while other services have issued Hold or Sell opinions. The reported consensus rating is Hold, highlighting both the substantial upside analysts see and the risks surrounding this early-stage biotech.
• Neutral Sentiment: Shareholder actions expand financing capacity: Stockholders elected directors and approved an expansion of the equity plan by 1 million shares. The authorization may provide capital for development, but it also creates potential future dilution for existing shareholders. NeOnc Stockholders Elect Directors, Approve Equity Plan Expansion
• Negative Sentiment: Recent earnings results were weak: NeOnc reported a quarterly loss of $0.58 per share, significantly wider than the $0.12 loss analysts expected. The miss underscores the company’s ongoing cash-burn and execution risks while its clinical programs remain in development.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.